BIO241220C280000
- 36.16
- 0.000.00%
Bio-Rad Laboratories Newsroom
A Quick Look at Today's Ratings for Bio-Rad Laboratories(BIO.US), With a Forecast Between $360 to $469
Bio-Rad Laboratories Is Maintained at Outperform by RBC Capital
Bio-Rad Laboratories Analyst Ratings
RBC Capital Maintains Bio-Rad Laboratories(BIO.US) With Buy Rating, Raises Target Price to $469
Citi Maintains Bio-Rad Laboratories(BIO.US) With Buy Rating, Raises Target Price to $450
RBC Capital Maintains Bio-Rad Laboratories(BIO.US) With Buy Rating, Raises Target Price to $446
Bio-Rad Laboratories (BIO) Gets a Buy From RBC Capital
Analysts Offer Insights on Healthcare Companies: Xencor (XNCR), Argenica Therapeutics Ltd (AU:AGN) and Bio-Rad Laboratories (BIO)
Bio-Rad Upped by Citi to Buy; Charles River, Hologic Downgraded
Bio-Rad Laboratories Analyst Ratings
Citi Upgrades Bio-Rad Laboratories(BIO.US) to Buy Rating, Raises Target Price to $400
Nephron Initiates Bio-Rad Laboratories(BIO.US) With Buy Rating, Announces Target Price $390
Jefferies Maintains Bio-Rad Laboratories(BIO.US) With Hold Rating, Raises Target Price to $340
Bio-Rad Laboratories Analyst Ratings
RBC Capital Maintains Bio-Rad Laboratories(BIO.US) With Buy Rating, Maintains Target Price $401
Bio-Rad Laboratories (BIO) Receives a Buy From RBC Capital
Bio-Rad Laboratories Analyst Ratings
RBC Trims Price Target on Bio-Rad Laboratories to $401 From $402, Keeps Outperform Rating
RBC Capital Maintains Bio-Rad Laboratories(BIO.US) With Buy Rating, Cuts Target Price to $401
Citi Maintains Bio-Rad Laboratories(BIO.US) With Hold Rating, Raises Target Price to $350